Project Leader: Dr Bryan Yeung, Novartis Institute of Tropical Diseases, Singapore
Partners: Genomics Institute of the Novartis Research Foundation USA; Novartis Natural Products Research, Switzerland; Swiss Tropical and Public Health Institute, Switzerland; BPRC, the Netherlands and Wellcome Trust, UK
MMV Project Director: Dr Brice Campo
This collaboration is focused on discovering new molecules that could become a radical cure for P. vivax malaria. With this goal in mind the team is developing new biological assays to help identify such molecules.
Early discovery projects – by their very nature – have high rates of attrition. While a specific project might fail, the resources, including expertise and equipment remain nonetheless valuable. In response to this, MMV pioneered the miniportfolio model. The model assures flexibility in allocation of resources – established between MMV and a Pharmaceutical or Biotechnology partner – from one project to another. In this way, resources are utilized as efficiently as possible.
Our partners provide drug discovery expertise, and many further contributions both in-kind and financial. Each miniportfolio agreement has allowed us access to new compound libraries for high content screening. And each library provides us with an immense treasure trove of new starting points for medicinal chemistry to feed the entire pipeline.